label expans upgrad buy pt
bounc print share fell without reason
know past month wouldv like bottom
tick felt would beat unsur beat
would suffici still feel share discount nice
high especi upcom data could spur label expans stemi
data aha chicago potenti greatli increas
number heart attack benefit impella data set
pilot studi evalu safety/feas could lead pivot studi
could drastic increas use impella heart attack victim
arguabl cleanest stori share valuat
cheap feel robust cash posit high margin potenti
indic expans lack competit support argument
premium multipl pt base mo sale estimate
peg likelihood compel stemi data strong there
reason impella go shock
mani lack perfus variou organ even full shock
heart attack victim go shock posit data
could expand shock indic shock mortal cut
half impella expect heart attack without shock may see
reduct mortal treat open
occlus depend data outcom like run
pivot studi includ non-shock pt variat pt
left main disease/ren failur learn lot aha
initi read may complex believ data set
discuss lead higher share price fact late
breaker doc enrol hard-to-envis trial make us feel
data compel doc would scare open blockag
first fail
valuat upgrad share buy pt base
mo revenu estim
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
compani report world-wide impella revenu reflect
improv y/i impella revenu better
forecast impella patient util support equal
growth protect pci shock meanwhil ou impella revenu
bit shi forecast mainli due greater currenc impact
anticip constant currenc basi eu revenu grew
germani grow meanwhil revenu japan quarter
ytd japan revenu total given better traction date
manag improv revenu outlook japan vs
previous japan compani plan target center fiscal year vs
previous overal seem driver impella momentum remain
gross margin flat year year vs last year y/i
pressur attribut manufactur invest direct labor
cost intend support top-lin growth note manag indic
produc inventori anticip support growth sg
spend better model despit higher cost
associ train program conference-rel expens lastli
 slightli ahead overal ebit margin
better model ep includ excess
tax benefit relat stock-bas comp
actualsbtig estimate varianceu impella sale trial impella sale revenu growth net incom bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani estim non- exclud incom tax benefit relat stock option
rais revenu forecast
incorpor upsid increas spend assumpt
trim sg spend estim lead net ebit margin
compar favor prior forecast ep
forecast includ tax benefit recogn importantli
forecast benefit go forward thu estim may
directli compar street estim
rate buy pt base month
revenu estim current trade ntm revenu feel
compani above-averag revenu growth gross margin warrant
premium multipl peer importantli feel multipl
driver potenti upsid street estim includ label expans
stemi popul sizabl treatment pool previous
estim via use diseas area like renal failur acut kidney
injuri geograph reach market risk rate price
target includ reimburs slippag product timelin chang
procedur patent litig data fda
exhibit comp tabl fast-grow med-tech compani
impella sale impella sale net incom btig estim compani model tax benefit go-forward basi estim may directli compar consensu forecast newold changentm inc ingnnot factset data btig estimatespr ex-amortev/salescagrcompanytickerr ptpricemarket cap
abiom incom product fund total y/i good gross sg amort intangibles- total oper incom loss invest incom incom incom expens pre-tax incom incom gaap net incom gaap share non-gaap non-gaap non-gaap ex select calendar loss net product product product oper ep btig estim compani report
abiom revenu commercialnew impella unit asp stock impella cp cp unit cp asp cp stock impella unit asp stock impella rp rp unit rp asp rp stock stock y/i consol instal rate new growth impella y/i inventori inventori impella impella product trial impella impella product product y/i product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
